ScholarIQanswers from OpenAlex & ORCID
Douglas B. Evans
ResearcherPublications, citations & collaboration network
Douglas B. Evans is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Douglas B. Evans have?
ScholarIQindexed works
Douglas B. Evans has 843 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Douglas B. Evans have?
ScholarIQcitation count
Douglas B. Evans has 52,449 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Douglas B. Evans?
ScholarIQh-index
Douglas B. Evans has an h-index of 113 in OpenAlex.
What is the i10-index of Douglas B. Evans?
ScholarIQi10-index
Douglas B. Evans has an i10-index of 421 in OpenAlex.
What is the ORCID of Douglas B. Evans?
ScholarIQorcid
The ORCID for Douglas B. Evans is on the source record.
What is the OpenAlex record for Douglas B. Evans?
ScholarIQopenalex
The OpenAlex for Douglas B. Evans is on the source record.
What are the most-cited papers on Douglas B. Evans?
ScholarIQmost cited works
One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
James C. Yao, Manal M. Hassan, Alexandria T. Phan, Cecile G. Dagohoy, Colleen Leary, Jeannette E. Mares, Eddie K. Abdalla, Jason B. Fleming, Jean‐Nicolas Vauthey, Asif Rashid, Douglas B. Evans
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
Samuel A. Wells, L. Sylvia, Henning Dralle, Rossella Elisei, Douglas B. Evans, Robert F. Gagel, Nancy Y. Lee, Andreas Machens, Jeffrey F. Moley, Furio Pacini, Friedhelm Raue, Karin Frank‐Raue, Bruce Robinson, M. Sara Rosenthal, Massimo Santoro, Martin Schlumberger, Manisha H. Shah, Steven G. Waguespack
Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas
Maria A. Kouvaraki, Jaffer A. Ajani, Paulo M. Hoff, Robert A. Wolff, Douglas B. Evans, Richard D. Lozano, James C. Yao
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Christiane J. Bruns, Matthew T. Harbison, Darren W. Davis, Charles A. Portera, Rachel Tsan, David J. McConkey, Douglas B. Evans, James L. Abbruzzese, Daniel J. Hicklin, Robert Radinsky
Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma.
Peter W. T. Pisters, James L. Abbruzzese, Nora A. Janjan, Karen R. Cleary, Chusilp Charnsangavej, M.S. Goswitz, Tyvin A. Rich, Isaac Raijman, Robert A. Wolff, Renato Lenzi, J E Lee, Douglas B. Evans